Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 12/20 | 0.40 |
| ▸ | GHSR | Q92847 | 4/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30256409 | 1.00 | PARP1 (0.43) | PARP1PTGDR2KEAP1GHSRNFE2L2 | |
| SCHEMBL23930760 | 0.90 | PARP1 (0.45) | PARP1PTGDR2KEAP1NFE2L2ATM | |
| SCHEMBL30256353 | 0.90 | KEAP1 (0.44) | PARP1PTGDR2KEAP1NFE2L2ATM | |
| SCHEMBL25264776 | 0.90 | KEAP1 (0.44) | PARP1PTGDR2KEAP1NFE2L2ATM | |
| SCHEMBL25187459 | 0.90 | KEAP1 (0.44) | PARP1PTGDR2KEAP1NFE2L2ATM | |
| SCHEMBL23959356 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL30256146 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL25555241 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL30533745 | 0.84 | KEAP1 (0.44) | KEAP1NFE2L2ATML3MBTL1ALDH1A1 | |
| SCHEMBL24174323 | 0.84 | KEAP1 (0.41) | PARP1KEAP1GHSRNFE2L2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4139295-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4x Discovery Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | PARP1 950/4885PTGDR2 1644/4885KEAP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.